Academic Perspectives for Evaluating, Identifying, and Managing CRS

Panelists discuss the recommendations for evaluating, identifying, and managing cytokine release syndrome (CRS), covering the pretreatment phase, patient education, treatment location, premedications, CRS management, dose modifications, and the community oncology perspective.

EP: 1.Intro and Overview of Bispecifics in Non-Hodgkin Lymphoma (NHL)

EP: 2.CD3×CD20 Bispecific Toxicities and Consensus Recommendations for Managing

EP: 3.Community Oncologist Perspective: CD3×CD20 Bispecific Toxicities and Consensus Recommendations

EP: 4.Protocol Development for Administration and AE Management of Bispecifics

EP: 5.Community Oncologist Perspective: Protocol Development for Bispecific Administration and AE Management

EP: 6.Exploring the Management of Cytokine Release Syndrome (CRS)

Now Viewing

EP: 7.Academic Perspectives for Evaluating, Identifying, and Managing CRS

EP: 8.Community Oncologist Perspective: Evaluating, Identifying, and Managing CRS

EP: 9.Clinical Recommendations for Neurological Toxicities

EP: 10.Community Oncologist Perspective: Clinical Recommendations for Neurological Toxicities

EP: 11.Management of BsAb Toxicities by Community Oncologists Across Therapeutic Indications

EP: 12.Community Oncologist Perspective: Initiation, Hospitalization, and Monitoring of Bispecifics

EP: 13.Patient Referrals of Bispecifics and Collaborative Efforts with Community Centers

EP: 14.Perceptions on the Future of Bispecific Therapies for NHL

EP: 15.Community Oncologist Perspective: Future of Bispecific Therapies for NHL

Video content above is prompted by the following:

• What are the recommendations for evaluating, identifying, and managing cytokine release syndrome (CRS)?
• Pretreatment phase
• Patient education and monitoring
• Treatment location
• Premedications
• Management of CRS
• Dose modifications and retreatment
• Community oncology perspective

Recent Videos